Freeze-dried live attenuated smallpox vaccine prepared in cell culture “LC16-KAKETSUKEN”: Post-marketing surveillance study on safety and efficacy compliant with Good Clinical Practice  by Nishiyama, Yasumasa et al.
F
“
a
Y
H
a
b
c
d
a
A
A
K
A
L
L
P
S
E
1
S
(
T
h
0Vaccine 33 (2015) 6120–6127
Contents lists available at ScienceDirect
Vaccine
j o ur na l ho me  page: www.elsev ier .com/ locate /vacc ine
reeze-dried  live  attenuated  smallpox  vaccine  prepared  in  cell  culture
LC16-KAKETSUKEN”:  Post-marketing  surveillance  study  on  safety
nd  efﬁcacy  compliant  with  Good  Clinical  Practice
asumasa  Nishiyamaa, Tatsuya  Fujii a, Yasuhiro  Kanatanib, Yasuhiko  Shinmurac,∗,
iroyuki  Yokotec,  So  Hashizumed
Health Care Center, Japan Self-Defense Forces Central Hospital, 1-2-24 Ikeziri, Setagaya-ku, Tokyo 154-8532, Japan
National Institute of Public Health, 2-3-6 Minami, Wako-shi, Saitama 351-0197, Japan
The Chemo-Sero-Therapeutic Research Institute (Kaketsuken), 1-6-1 Okubo, Kita-ku, Kumamoto-shi, Kumamoto 860-8568, Japan
Chiba University, 1-33, Yayoicho, Inage Ward, Chiba-shi, Chiba 263-8522, Japan
 r  t  i  c  l e  i  n  f  o
rticle history:
vailable online 9 October 2015
eywords:
ttenuated smallpox vaccine
C16m8
C16-KAKETSUKEN
ostmarketing surveillance study
afety
fﬁcacy
a  b  s  t  r  a  c  t
Background:  In Japan,  production  of smallpox  vaccine  LC16m8  (named  LC16-KAKETSUKEN)  was  restarted
and was  determined  to be  maintained  as  a national  stockpile  in  March  2002.
Objective:  To  conduct  a  post-marketing  surveillance  study  of  the  vaccination  of  freeze-dried  live  atten-
uated  smallpox  vaccine  prepared  in  cell  culture  LC16-KAKETSUKEN  using  attenuated  vaccinia  strain
LC16m8.  The  study  complied  with  Good  Clinical  Practice,  focusing  on  a comparison  between  primary
vaccinees  and  re-vaccinees.
Method: 268  personnel  (261  males  and  7 females)  of the  Japan  Ground  Self-Defense  Force  were  inoculated
with  LC16-KAKETSUKEN  and thereafter  adverse  events  and  efﬁcacy  were  evaluated.
Results: Among  268  vaccinee  participants,  the  following  vaccinees  showed  adverse  events,  none  serious:
53  of 196  primary  vaccinees  (without  previous  smallpox  vaccination),  4  of 71 re-vaccinees  (with previ-
ous  smallpox  vaccination)  and  1  vaccinee  with  unknown  previous  vaccination  history.  A breakdown  of
adverse  events  observed  in this  study  (total  268  vaccinees)  showed  the  following  minor  or mild  adverse
events:  52  (19.4%)  swelling  of  axillary  lymph  node,  4 (1.5%)  fever,  2 (0.7%)  fatigue, 1  (0.4%)  of rash,  14
(5.2%)  erythema  at the  inoculation  site,  1  (0.4%)  swelling  at the  inoculation  site  and  1  (0.4%)  autoinocula-
tion.  The  incidence  of adverse  events  for primary  vaccinees  (53/196;  27.0%)  was  signiﬁcantly  higher  than
for  re-vaccinees  (4/71;  5.6%).  However,  the  proportion  of  vaccine  take was  signiﬁcantly  higher  for  pri-
mary  vaccinees  (185/196;  94.4%)  than for  re-vaccinees  (58/71;  81.7%).  Although  the  proportion  of vaccine
take of  re-vaccinees  was  signiﬁcantly  lower  than  for  primary  vaccinees  due  to preexisting  immunity  by
previous vaccination,  no  signiﬁcant  difference  was found  in  neutralizing  antibody  titers  between  primary
vaccinees  and  re-vaccinees  at  1, 4 and  7 months  after  LC16-KAKETSUKEN  vaccination.
Conclusion: The  present  post-marketing  surveillance  study  compliant  with  Good  Clinical  Practice  demon-
strated  the  efﬁcacy  and  safety  of  the  smallpox  vaccine  LC16-KAKETSUKEN  in  an  adult  population.
LC16-KAKETSUKEN  is  the  sole  currently  available  licensed  smallpox  vaccine  for both  adult and  pediatric
populations.
ublis© 2015  The  Authors.  P
. IntroductionIn the early 1970s, Hashizume et al. [1,2], then at the Chiba
erum Institute (CSI), Chiba, Japan, developed an attenuated
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tissue-cultured smallpox vaccine, LC16m8, from the Lister
(Elstree) original strain that was  used worldwide in the World
Health Organization (WHO) smallpox eradication program [1,2].
LC16m8 was vaccinated into more than 50,000 children in Japan
during 1973–1974, without showing problematic adverse events,
such as postvaccinal encephalitis, progressive vaccinia, and skin
complications, including autoinoculation, postvaccinal exanthems
and eczema vaccinatum. Based on these studies, the vaccine strain
LC16m8 was  licensed in 1975 in Japan, and its freeze-dried vaccine
preparation was also licensed in 1980. Because of the success of
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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he smallpox eradication program, and followed by the declaration
f its success by WHO  in 1980, a regular vaccination program was
nded in 1976 and smallpox vaccination was legally abolished in
980 in Japan. Therefore, the LC16m8 strain is unlikely to show its
ffectiveness against endemic smallpox. However, the situation
urrounding smallpox vaccination has changed dramatically after
he incidents of September 2001 in the U.S.A., because concern
bout bioterrorism has risen. Among many pathogens, variola
irus is one of the most feared.
Under such a situation, serious attempts have been made,
oth at home and abroad, to restart the development of small-
ox vaccines with lower virulence compared with conventional
accines. A vaccinia ACAM1000 clone established using cell cul-
ures from the Dryvax vaccine may  induce myocarditis [3,4].
odiﬁed vaccinia virus Ankara and NYVAC (modiﬁed Copenhagen
train) replication-incompetent viruses are certainly safer, but
ay  require high vaccine doses, multiple doses or boosting with
eplication-competent vaccines [5,6]. LC16m8 vaccine has drawn
enewed attention as a promising vaccine against bioterrorism
ecause it is a highly attenuated live vaccine prepared in cell cul-
ures. Of note, a 2013 WHO  Strategic Advisory Group of Experts
eeting on Immunization recommended both licensed ACAM2000
2nd generation vaccine) and LC16m8 (3rd generation vaccine) as
referred WHO  stockpile vaccines [7].
The history of LC16m8 vaccine after its licensing in 1975 in Japan
s brieﬂy as follows. Kaketsuken started in March 2002 in Japan
o manufacture national stockpile vaccine recently named LC16-
AKETSUKEN as a medical countermeasure against bioterrorism as
 result of the incident of September 11, 2001. Kaketsuken is man-
facturing LC16-KAKETSUKEN from the master virus seed (MVS)
ransferred from CSI by using the modiﬁed manufacturing proce-
ure of CSI as described in Section 3. Its efﬁcacy and safety was
hown in mice, rabbits and monkeys [8–13]. A study on the safety
nd efﬁcacy in adult populations was done by using the vaccine
anufactured by CSI (licensed LC16m8 vaccine, lot No. Chiba 02):
he LC16m8 vaccine was inoculated from 2002 into personnel of the
apan Ground Self-Defense Force (JGSDF), showing its good efﬁcacy
nd safety [14].
The series of clinical studies of this post-marketing surveil-
ance (PMS) study were done under Good Clinical Practice (GCP)
ompliant conditions to conﬁrm the safety and immunogenicity of
C16-KAKETSUKEN in members of JGSDF with detailed background
nformation and with an extended follow up of neutralizing anti-
ody titers until 7 months after vaccination. Clinical data on adult
opulations in the Package Insert of LC16-KAKETSUKEN were also
sed.
Number of participants included  
in safety study: 268
Numb
stu
Number of participants  
Excluded from safety study: 0
N
e
Numb
e
N
s
A
Number of participants with recovered
ig. 1. Flow of participants through the study. This ﬁgure shows the ﬂow of participants
ake  of LC16-KAKETSUKEN and by neutralizing antibody titers in the serum after vaccinat
andomly from 268 participants.33 (2015) 6120–6127 6121
2. Material and methods
This study was  done from June 6, 2005, through to March 31,
2010, under the initiative of principal investigator Tatsuya Fujii,
MD in the Department of Internal Medicine, Self-Defense Forces
Central Hospital.
2.1. Vaccine and vaccination
LC16-KAKETSUKEN vaccine, a freeze-dried live attenuated
smallpox vaccine prepared in cell culture, containing a suspension
of greater than 1 × 108 pock-forming units (pfu)/mL of the LC16m8
strain as the only virus component, was  used. The process of estab-
lishing LC16-KAKETSUKEN vaccine by modifying the method of CSI
is described in Section 3. This vaccine was  reconstituted with 0.5 mL
of the packaged vaccine diluent (water for injection, containing
20, volume per volume % of glycerin) and 0.01 mL  was inoculated
into the skin. Inoculation was  done by physicians who received
the instructions and training of the vaccination method by using
designated bifurcated needles. Pressure pricking (puncture) was
done 5 times for primary vaccinees (without previous smallpox
vaccination) and 10 times for re-vaccinees (with previous smallpox
vaccination).
2.2. Participants
The Self-Defense Forces Central Hospital planned and organized
the smallpox vaccination program for selected personnel in the
JGSDF. Participants were JGSDF personnel who were scheduled
for deployment in International Peacekeeping Operation activities
of the United Nations Disengagement Observer Force [15], except
for personnel who did not comply with the implementation guid-
ance of smallpox vaccine inoculation of JGSDF and personnel who
were described as ineligible for vaccination or as being contraindi-
cated according to the Package Insert of the LC16-KAKETSUKEN.
The following items were conﬁrmed before vaccine inoculation:
no abnormality in the blood, biochemical and urea tests, negativity
of hepatitis B virus antigens and hepatitis C virus antibodies, and
no infection with human immunodeﬁciency virus. Vaccine inoc-
ulation was  contraindicated for participants who  were pregnant,
under immunosuppression or with eczema, and participants who
receive live vaccine within 30 days. The participants were 268 vol-
unteers who were vaccinated with LC16-KAKETSUKEN in this PMS
study. All the participants were given instructions to avoid contact
with pregnant women and newborn babies within one month after
er of p artic ipants  includ ed  in effic acy 
dy (proportio n of va ccine take):  268
umber of p artic ipants  exclud ed fro m 
ffica cy stud y (vac cine  take): 0
er  of  randomly  selec ted  participan ts in clud ed in 
fficacy  stud y (neutraliz ing  an tibody):  10 0
umber  of  partic ipants  exclud ed from efficacy 
tudy (neutralizing antibody): 168
nt ibody te st was  no t don e. 
 survey slip: 268
 in safety and efﬁcacy studies. Efﬁcacy was evaluated by the proportion of vaccine
ion with the vaccine. The 100 participants included in efﬁcacy study were selected
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noculation. All the participants were distributed individually with
dhesive tape for the inoculation site.
Fig. 1 shows the ﬂow of participants through the study. The
otal number of participants was 268: 261 males and 7 females.
he average age was 29.2 (19–52): 9 were born before 1961, 43
ere born from 1962 to 1968, 57 were born from 1969 to1975
nd 159 were born after 1976 (see also Table 3). Because small-
ox vaccination continued until 1976 in Japan, participants born
efore 1976 had a high possibility to have had previous vaccina-
ion (re-vaccinees). The discrimination between primary vaccinees
nd re-vaccinees was done by taking into account the age and the
resence or absence of a vaccination scar. Among 268 vaccinee par-
icipants, 71 (26.5%) were judged to be re-vaccinees, 196 (73.1%) to
e primary vaccinees and 1 (0.4%) was unknown. An examination
or allergy showed that 10 (3.7%) experienced some sort of aller-
ic history, such as pollen allergy. No participants with immune
eﬁciency were found and most of them had a history of receiving
accination for hepatitis A, B and other-non-hepatitis vaccines.
.3. Blood pressure and clinical laboratory test results
Immediately before and one month after inoculation, the fol-
owing tests were done and the obtained data were investigated
nd analyzed: blood pressure, blood tests (numbers of leukocytes
nd red cells, hemoglobin value, hematocrit value, number of blood
latelets), biochemical tests (total cholesterol, whole protein, albu-
in, urea nitrogen, uric acid, creatinine, total bilirubin, aspartate
minotransferase, alanine aminotransferase, lactase dehydroge-
ase, alkaline phosphatase, C-reactive protein, blood glucose and
rinalysis (protein, glucose)).
.4. Vaccine take, examination of adverse events and local
ndings
At 10–14 days after inoculation, physicians who  had received
he required training engaged judged the vaccine take and exam-
ned participants for the presence of adverse events and local
ndings.
.5. Neutralizing antibody assayNeutralizing antibody assay was done for blood samples col-
ected 1, 4 and 7 months after inoculation from 100 participants
able 1
ummary of adverse events.
Previous smallpox v
No 
Number of participants 196 
Number of participants with adverse events 53 
Number of adverse events 71 
Incidence of adverse eventsa 27.0% 
Type  of adverse event Incidence of each a
Autoinoculation following vaccinationb 0 
Swelling of axillary lymph node 50 (25.5) 
Rash  0 
Systemic disorders
Fatigueb 2 (1.0)
Fever  2 (1.0) 
Local  disorders at inoculation site
Erythema at inoculation siteb 14 (7.1) 
Swelling at inoculation siteb 1 (0.5) 
Complications associated with vaccinationb 2 (1.0) 
oding by MedDRA Ver.12.1.
a Number of participants with adverse events/number of participants × 100.
b Adverse events unpredictable from PRECAUTIONS.33 (2015) 6120–6127
selected randomly. Neutralizing antibody titers against Lister
vaccinia virus strain were assessed by the plaque reduction neu-
tralization test assay [14,16]. The neutralizing antibody titer was
deﬁned as the reciprocal of the dilution level resulting in a 50%
reduction of total plaques formed by Lister vaccinia virus strain
with no treatment by vaccinated sera. Vaccinees showing 4 or more
in the ratio of maximal post-inoculation titers to pre-inoculation
titers were judged as a positive conversion.
2.6. Data analysis
Signiﬁcant differences in the frequency of adverse events and
vaccine take between primary vaccinees and re-vaccinees were
determined using the Steel test and the Wilcoxon rank sum test.
The Fisher exact probability test and the Steel test were used to
compare geometric mean titers of neutralizing antibodies. Statis-
tical analyses were done using SAS/Base/Stat, version 8.0.2. or the
updated version.
2.7. Ethical notice
This study was done according to the guidelines of clinical stud-
ies and was  approved by the institutional review board of the
JGSDF Central Hospital (No. 16-004; August 30, 2004: No. 18-022;
December 21, 2006).
3. Results
3.1. Improvement of vaccine production process
The amount of MVS  of the LC16m8 strain transferred from
CSI was  limited and therefore we  started to produce LC16-
KAKETSUKEN by a procedure modiﬁed as follows. The number of
passages from MVS  to vaccine product was extended from 2 to 3
to make production more efﬁcient, but this modiﬁcation resulted
in generating some revertant mutants that form slightly larger
plaques than plaques formed by the original MVS. Because the
contents of these revertant mutants in the primary passage prepa-modiﬁed to produce a primary passage preparation that contains
a smaller amount of revertant mutants to a level similar to that of
the original MVS.
accination history Total
Yes Unknown
71 1 268
4 1 58
5 1 77
5.6% 100% 21.6%
dverse event (%)
1 (1.4) 0 1 (0.4)
2 (2.8) 0 52 (19.4)
0 1 (100.0) 1 (0.4)
0 0 2 (0.7)
2 (2.8) 0 4 (1.5)
0 0 14 (5.2)
0 0 1 (0.4)
0 0 2 (0.8)
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Fig. 2. Time course of neutralizing antibody titers in the serum after vaccination.
The time course of neutralizing antibody titers was examined for both primary vac-Y. Nishiyama et al. / Va
.2. Incidence of adverse events
Table 1 summarizes the adverse events, and Table 2 shows
dverse events for each background of vaccinees. Among 268 vacci-
ee participants, the following vaccinees showed adverse events:
3 of 196 primary vaccinees, 4 of 71 re-vaccinee and 1 vaccinee
articipant with unknown previous vaccination history. Swelling
f the axillary lymph node was observed for 50 of 196 primary vac-
inees and 2 of 71 re-vaccinees. Thus, primary vaccinees showed
 higher incidence of adverse events, including lymphoadenopa-
hy, than re-vaccinees. The breakdown of adverse events of a total
8 of 268 vaccinees was: 52 vaccinees with swelling of the axillary
ymph node, 4 vaccinees with fever, 2 vaccinees with fatigue, 1 vac-
inee with a rash, 14 vaccinees with erythema at the inoculation
ite, 1 vaccinee with swelling at the inoculation site and 1 vac-
inee with autoinoculation. Complications with vaccination were
bserved for 2 primary vaccinees. One complication was  allergic
ermatitis that was not eczema vaccinatum and the vaccinee recov-
red without supportive care. The other case was a rash unrelated
o the vaccination.
All the adverse events were mild and no serious events (related
o cardiovascular disorder, encephalitis, accessory vaccinia or
atellite lesions, or progressive vaccinia) were observed. Elec-
rocardiography examination was done for all participants, who
lso received both chest X-ray and electrocardiogram examina-
ions. Adverse events related to cardiovascular disorder were not
bserved, except for 2 vaccinees with electrocardiography exami-
ation (1st degree atrioventricular block). Both of these vaccinees
ere re-vaccinees; one of them had no special past and present
isorder history, while the other had a history of allergy his-
ory. However, their disorder was mild and therefore a causality
etween this disorder and the vaccination was  denied. Adverse
vents related to encephalitis or those related to accessory vac-
inia and progressive vaccinia was not observed. No subject died
uring this research.
.3. Blood pressure and clinical tests (data not shown)
Some vaccinees showed changes in total cholesterol, glutamic-
yruvic transaminase and number of leukocytes before and after
accination. However, all changes were considered to be due to
hanges in daily habit or transiently catching a cold, and were
udged to be not due to vaccination. Abnormality of blood pressure
ccompanied by vaccination was also not observed.
.4. Vaccine take
Table 3 shows the examination of vaccine take for each back-
round of vaccinees. All 268 vaccinees were analyzed. Vaccine
ake was positive for 244 (91.0%) vaccinees and was  negative
or 24 (9.0%) vaccinees. Primary vaccinees showed a statistically
igher proportion of vaccine take (94.4%; 185/196) than that shown
y re-vaccinees (81.7%; 58/71) (Odds ratio at 95% conﬁdential
nterval = 0.265; 0.113–0.624). The diameter of erythema was sig-
iﬁcantly larger (P < 0.001, Wilcoxon rank sum test) for primary
accinees than for re-vaccinees, and the diameter of a blister was
arger for primary vaccinees than for re-vaccinees without sta-
istical signiﬁcance (P = 0.277, Wilcoxon rank sum test) (data not
hown).
Notably, vaccinees with erythema less than 10 mm in diameter
ad a lower proportion of vaccine take (87.5%) compared with
ther vaccinees with erythema 10 mm or more, all showing 100%
roportion of vaccine take (Table 3). Younger vaccinees tended
o show a relatively higher proportion of vaccine take than older
accinees, probably because most younger vaccinees were primary
accinees (Table 3). We  observed no clear difference in proportioncinees and re-vaccinees. Of note, the titer of one primary vaccinee changed from
seropositive to seronegative (<8) at 7 months after inoculation. See the method for
titration in Section 2.
of vaccine take dependent on the history of previous disorders,
current medical history, history of allergy and side effects, history
of other vaccinations and usage of drugs in combination.
3.5. Level of neutralizing antibody responses
Fig. 2 and Table 4 show the results of neutralizing antibody titers
and seroconversion rate, respectively. Among 268 vaccinees, the
neutralization antibody titer in the serum was determined for 100
randomly selected vaccinees (Fig. 2) done as follows: 99 vaccinees
before vaccination (0 month), 51 vaccinees at 1 month, 46 vacci-
nees at 4 months and 53 vaccinees at 7 months after vaccination.
While primary vaccinees showed a statistically higher seroconver-
sion rate at 1, 4 and 7 months after vaccination than that shown
by re-vaccinees, primary vaccinees tended to show equivalent or
lower antibody titers without exception at 0, 1, 4 and 7 months
after vaccination compared with re-vaccinees (Fig. 2 and Table 4).
However, both vaccinees kept higher antibody titers even at 7
months after vaccination than those vaccinees at 0 month (Fig. 2).
Younger vaccinees tended to show a higher seroconversion rate
than older vaccinees, probably because most older vaccinees still
had a high neutralizing antibody titer elicited by previous vac-
cinations (Table 4 and Fig. 2). A statistically signiﬁcant positive
correlation (P < 0.001, Fisher exact probability test) was  observed
between vaccine take and seroconversion (data not shown).
4. Discussion
We showed that LC16-KAKETSUKEN is safe and effective in
an adult population at a level similar to that of the previous
LC16m8 vaccine (Lot No. Chiba 02) manufactured by the CSI [14].
The following points are especially noted. (1) A clinical study on
LC16-KAKETSUKEN, produced by using the improved manufactur-
ing process, was  done for the ﬁrst time strictly compliant with
GCP under the approval of the Ministry of Health, Labor and Wel-
fare (MHLW). (2) To evaluate the safety of LC16-KAKETSUKEN, the
background of the participants was  examined and was described in
detail for more than 15 items, such as history of allergy and vacci-
nation with various vaccines, including smallpox vaccine, previous
diseases and existence or non-existence of immune deﬁciency.
Such a detailed background of patients was not described in our
previous clinical study [14]. (3) Neutralizing antibody titers were
monitored until 7 months after LC16m8 vaccination, much longer
than in the previous study [14]. A detailed comparison between
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Table 2
Adverse events and vaccine take for each background of vaccinees.
Background of vaccinees Primary vaccinees Re-vaccinees
No. of vaccines No. of adverse events Rate of adverse
events (%)
No. of vaccines No. of adverse events Rate of adverse
events (%)
Total 196 53 27.0 71 4 5.6
Gender
Male  190 53 27.9 70 4 5.7
Female 6 0 0 1 0 0
Age  at vaccination with LC16-Ka vaccine (year)
≥50 0 0 0 1 0 0
40–49 6 1 16.7 20 0 0
30–39  31 5 16.1 50 4 8.0
20–29  158 46 29.1 0 0 0
<20  1 1 100 0 0 0
Body  weight
<65 kg 51 19 37.3 13 1 7.7
65–70  kg 47 16 34.0 7 1 14.3
70–75  kg 42 8 19.0 17 2 11.8
≥75  kg 40 10 25.0 17 0 0
Unknown 16 0 0 17 0 0
History of previous disorder
No 195 53 27.2 71 4 5.6
Yes  1 0 0 0 0 0
Current medical history
No 195 53 27.2 68 3 4.4
Yes  1 0 0 3 1 33.3
History of allergy and side effects
No 188 52 27.7 69 4 5.8
Yes  8 1 12.5 2 0 0
Breakdown of allergy and side effects
Drugs 1 1 100 1 0 0
Others 7 0 0 1 0 0
Breakdown of vaccination history
Hepatitis A 195 52 26.7 71 4 5.6
Hepatitis B 195 52 26.7 71 4 5.6
Rabies 195 52 26.7 71 4 5.6
Tetanus toxoid 178 52 29.2 54 4 7.4
Polio  193 53 27.5 68 4 5.9
Abdominal typhus 192 51 26.6 69 4 5.8
Cerebral meningitis 190 51 26.8 69 4 5.8
Yellow fever 53 21 39.6 26 2 7.7
Japanese encephalitis 39 14 35.9 13 2 15.4
Drugs  used in combination
Allopurinol 0 0 0 1 0 0
Vaccine take of LC16-Ka.
No 11 1 9.1 13 1 7.7
Yes  185 52 28.1 58 3 5.2
Local  ﬁndings of LC16-Ka vaccine take
Blister 88 48 54.5 12 1 8.3
Ulcer  12 6 50.0 0 0 0
Crust  29 14 48.3 10 1 10.0
Swelling 15 9 60.0 3 0 0
Others 14 4 28.6 3 0 0
Unknown 79 0 0 36 1 2.8
Breakdown of LC16-Ka vaccine take – erythema
<10 mm 6 1 16.7 2 0 0
10–30  mm 54 27 50.0 10 2 20.0
≥30  mm 25 14 56.0 1 0 0
Unknown 3 0 0 1 0 0
Breakdown of LC16-Ka vaccine take – blister
≤5 mm 34 13 38.2 6 0 0
6  mm 4 3 75.0 0 0 0
7  mm 4 3 75.0 3 1 33.3
8  mm 14 9 64.3 1 0 0
75.0 
41.7 
p
v
K
e
P
I
w≥9  mm 20 15 
Unknown 12 5 
a LC16-KAKETSUKEN.
articipants with and without previous vaccination of smallpox
accine conﬁrmed the previous results [14]. Based on these results,
aketsuken could describe the present results of adults, along with
xisting clinical data collected from a pediatric population, in the
ackage Insert of LC16-KAKETSUKEN under the approval of MHLW.
n the package insert, the summary of this PMS  study (162 words)
as newly added, including explanation about participants, and1 0 0
1 0 0
the results of vaccine take and antibody titers, as well as adverse
events.
All studies on humans done hitherto, including this study, sup-
port the safety of LC16m8 vaccine, both in children [17] and
adults [14]. Also, animal studies on monkeys, rabbits and mice
[2,8,10,12,13] support the safety and protective efﬁcacy of LC16m8
vaccine. Notably, LC16m8 vaccine and its genetically modiﬁed
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Table  3
Proportion of vaccine take for each background of vaccinees.
Background of vaccinees Vaccine take (number) Proportion of vaccine take (%) Odds ratio (95% conﬁdential interval) or
comparative testa,b,c
Yes No
Total 244 24 91.0 (0.876–0.945)
Gender
Male  238 23 91.2
0.580 (0.067–5.027)
Female 6 1 85.7
Age  at vaccination with LC16-Kd vaccine (year)
≥50 1 0 100.0
Steel test
≤29 vs ≥50 <0.001 (<0.001–>999.999) p = 0.994
≤29 vs 40–49 5.663 (1.781–18.003) p = 0.004
≤29 vs 30–39 2.622 (0.993–6.924) p = 0.129
40–49  20 6 76.9
30–39 72 10 87.8
20–29 150 8 94.9
<20  1 0 100.0
Wilcoxon rank sum test Z = −2.989, p = 0.003
Body  weight
<65 kg 63 1 98.4
Wilcoxon rank sum test Z = 1.567, p = 0.117
65–70  kg 49 5 90.7
70–75 kg 54 6 90.0
≥75 kg 52 5 91.2
History of previous disorder
No 243 24 91.0
>999.999 (<0.001–>999.999)
Yes  1 0 100.0
Current medical history
No 240 24 90.9
>999.999 (<0.001–>999.999)
Yes  4 0 100.0
History of allergy/side effects
No 234 24 90.1
>999.999 (<0.001–>999.999)
Yes  10 0 100.0
Breakdown of allergy/side effects
Drugs 2 0 100.0 –
Foods 0 0 –
Breakdown of vaccination history
Hepatitis A 243 24 91.0
–
Hepatitis B 243 24 91.0
Rabies 243 24 91.0
Tetanus toxoid 216 17 92.7
Polio 239 23 91.2
Abdominal typhus 239 23 91.2
Cerebral meningitis 238 22 91.5
Yellow fever 72 8 90.0
Japanese encephalitis 48 5 90.6
History of previous smallpox vaccination
No 185 11 94.4
0.265 (0.113–0.624)Yes  58 13 81.7
Unknown 1 0 100.0
Drugs used in combination
No 243 24 91.0
>999.999 (<0.00–>999.999)
Yes  (Allopurinol) 1 0 100.0
Local ﬁndings of LC16-Kd vaccine take
Blister 100 0 100.0
–
Ulcer 12 0 100.0
Crust 40 0 100.0
Swelling 19 0 100.0
Others 15 2 88.2
Breakdown of LC16-Kd vaccine take/erythema
<10 mm 7 1 87.5
–10–30 mm 64 0 100.0
≥30 mm 26 0 100.0
Breakdown of LC16-Kd vaccine take/blister
≤5 mm 40 0 100.0
–
6  mm 4 0 100.0
7  mm 7 0 100.0
8  mm 15 0 100.0
≥9  mm 21 0 100.0
The bold value signiﬁes that the P value is under 0.05 or 0.01 and the 95% conﬁdential interval of Odds ration is under 1.0.
a The calculation of odds ratio or comparative test was  not done for unspeciﬁed items, such as “unknown” and “others”.
b The Steel test was  used as a multiple comparative technique.
c e inte
v
m
l
aOdds ratio (95% lower limit of conﬁdence interval–95% upper limit of conﬁdenc
d LC16-KAKETSUKEN.irus induced no serious adverse events in immunodeﬁcient ani-
als [2,13,18]. The protective ability of LC16m8 vaccine against
ethal challenge with the highly pathogenic vaccinia WR virus
ccompanied by induction of neutralizing antibodies to WR wasrval).shown for mice [12,16]. LC16m8 also protected monkeys from
monkeypox [8,13]. These animal studies provide supportive evi-
dence for the safety and efﬁcacy of LC16m8 vaccine, including
LC16-KAKETSUKEN, in humans.
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Table 4
Time course of seroconversion rate depending on smallpox vaccination history and age at vaccination.
Background of vaccinees Seroconversion rate (%)a Maximum
seroconversion
rate after
vaccinationb
Steel testc
After vaccination
(1 month)
After vaccination
(4 month)
After vaccination
(7 month)
Compared with 0 month Compared with 1 month
0 month vs 1
month
0 month vs 4
month
0  month vs 7
month
1  month vs 4
month
1  month vs 7
month
Total 72.5 (37/51) 71.7 (33/46) 62.3 (33/53) 72.7 (72/99) p < 0.001 p < 0.001 p < 0.001 p = 0.994 p = 0.432
History  of previous smallpox vaccination
No 84.2 (32/38) 89.3 (25/28) 75.0 (30/40) 86.8 (59/68) P < 0.001 P < 0.001 P < 0.001 p = 0.783 p = 0.506
Yes  33.3 (4/12) 44.4 (8/18) 16.7 (2/12) 40.0 (12/30) P = 0.003 P < 0.001 P = 0.066 p = 0.768 p = 0.546
Unknown 100.0 (1/1) – (0/0) 100.0 (1/1) 100.0 (1/1)
Fisher  exact probability test (No vs Yes) P = 0.002 P = 0.002 P = 0.001 P < 0.001
Age  at vaccination with LC16-KAKETSUKEN (year)
≥50 – (0/0) – (0/0) – (0/0) – (0/0) Test im.b Test im.b Test im.b p = 0.312 p = 0.432
40–49  66.7 (4/6) 28.6 (2/7) 33.3 (2/6) 46.2 (6/13) P = 0.004 P = 0.129 P = 0.089 p = 0.312 p = 0.432
30–39  40.0 (6/15) 60.0 (9/15) 35.3 (6/17) 50.0 (16/32) P = 0.001 P < 0.001 P = 0.001 p = 0.451 p = 0.948
20–29 89.7 (26/29) 91.7 (22/24) 82.8 (24/29) 92.5 (49/53) P < 0.001 P < 0.001 P < 0.001 p = 0.957 p = 0.672
<20  100.0 (1/1) – (0/0) 100.0 (1/1) 100.0 (1/1) Test im.b Test im.b Test im.b Test im.b Test im.b
Steel test
≤29 vs ≥50 Test im.d Test im.d Test im.d Test im.d
≤29 vs 40–49 P = 0.251 P = 0.001 P = 0.022 P < 0.001
≤29  vs 30–39 P = 0.001 P = 0.036 P = 0.002 P < 0.001
The bold value signiﬁes that the P value is under 0.05 or 0.01 and the 95% conﬁdential interval of Odds ration is under 1.0.
a Antibody titer after vaccination/before vaccination (0 month) ≥4 was  considered as positive seroconversion.
b Portion of the participants who seroconverted at one time point at least after vaccination.
c Steel test was conducted to compare the seroconvertion rate between the indicated time points.
d Test-im.: Test was  impossible.
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In the past, two severe cases of adverse events possibly caused
y vaccination with LC16m8 vaccine clinically were reported [14].
ne was a 26-year-old male primary vaccinee who  experienced
ash onset on day 3 after vaccination. The patient was  hospital-
zed for 20 days after vaccination. A skin biopsy from the rash was
onsistent with allergic dermatitis, which did not disprove a causal
elationship with vaccination. The other case was 29-year-old male
rimary vaccinee who developed a rash on his trunk on day 10 after
accination and was diagnosed with erythema multiform.
One of the major concerns with adult smallpox vaccination
as been myopericarditis observed in the United States vaccina-
ion program [19]. Inﬂammatory cardiac disease was  recognized
n adult recipients of Dryvax and ACAM2000 vaccine in the United
tates, but a study since then [14] and this PMS  study showed no
erious abnormality by electrocardiography examination.
In January 2011, based on the research ﬁndings of this PMS
tudy, the section of “Precautions for Use” in the Package Insert
or LC16-KAKETSUKEN was modiﬁed under the approval of MHLW
o ensure appropriate use for not only pediatric populations, but
lso for adult populations. Notably, according to the Package Insert
nd Product Information for ACAM2000 and IMVANEX (smallpox
accine derived from MVA  strain, Bavarian Nordic), vaccination
f pediatric populations is not authorized by national regulatory
uthorities now. Therefore, LC16-KAKETSUKEN is the sole currently
vailable smallpox vaccine for both adult and pediatric populations.
. Conclusion
From the safety and efﬁcacy results of this PMS  study that
omplied with GCP, smallpox vaccine LC16-KAKETSUKEN was con-
rmed to be a highly useful and excellent vaccine for both primary
accinees and re-vaccinees as judged from the absence of serious
dverse events, proportion of vaccine take and increase in neutral-
zing antibody titers.
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